Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss

In its lat­est push in­to the field of tar­get­ed pro­tein degra­da­tion, Astel­las has tapped fel­low Japan­ese com­pa­ny Pep­tiDream for a re­search col­lab­o­ra­tion and li­cens­ing deal.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes